Literature DB >> 18503979

GVHD pathophysiology: is acute different from chronic?

Tomomi Toubai1, Yaping Sun, Pavan Reddy.   

Abstract

Graft-versus-host disease (GVHD) is the major complication of allogeneic hematopoietic cell transplantation (HCT). GVHD occurs in acute and chronic forms. Acute GVHD usually manifests within 100 days following HSCT. It is induced by donor T cells responding to the mismatched host polymorphic histocompatibility antigens. Chronic GVHD generally manifests later (>100 days) and has some features of autoimmune diseases. It may develop either de novo or following resolution of - or as an extension of - acute GVHD. Chronic GVHD is also thought to be induced by donor T cells, but the nature of relevant antigens, the critical cellular subsets and the mechanisms of chronic GVHD remain less well understood. In this chapter we briefly discuss and contrast the pathophysiologies of acute and chronic GVHD.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18503979     DOI: 10.1016/j.beha.2008.02.005

Source DB:  PubMed          Journal:  Best Pract Res Clin Haematol        ISSN: 1521-6926            Impact factor:   3.020


  22 in total

1.  The benefit of exercise in patients who undergo allogeneic hematopoietic stem cell transplantation.

Authors:  Shinichiro Morishita; Atsuhiro Tsubaki; Kazuki Hotta; Jack B Fu; Shigeo Fuji
Journal:  J Int Soc Phys Rehabil Med       Date:  2019-05-22

2.  Extracorporeal photopheresis in the treatment of graft-versus-host disease: evidence and opinion.

Authors:  James W Hart; Lisa H Shiue; Elizabeth J Shpall; Amin M Alousi
Journal:  Ther Adv Hematol       Date:  2013-10

Review 3.  Pleiotropic effects of transforming growth factor-β in hematopoietic stem-cell transplantation.

Authors:  Stephanie M Coomes; Bethany B Moore
Journal:  Transplantation       Date:  2010-12-15       Impact factor: 4.939

4.  Graft-versus-host disease: part I. Pathogenesis and clinical manifestations of graft-versus-host disease.

Authors:  Sharon R Hymes; Amin M Alousi; Edward W Cowen
Journal:  J Am Acad Dermatol       Date:  2012-04       Impact factor: 11.527

5.  Human umbilical cord blood-derived stromal cells, a new resource in the suppression of acute graft-versus-host disease in haploidentical stem cell transplantation in sublethally irradiated mice.

Authors:  Cheng Zhang; Xing-Hua Chen; Xi Zhang; Lei Gao; Pei-Yan Kong; Xian-gui Peng; Xue Liang; Li Gao; Yi Gong; Qing-Yu Wang
Journal:  J Biol Chem       Date:  2011-02-24       Impact factor: 5.157

6.  Chronic graft versus host disease with small bowel obstruction after unrelated hematopoietic stem cell transplantation in a patient with acute myeloid leukemia.

Authors:  Ju Young Yoon; Hyery Kim; Hyoung Jin Kang; Kyung Duk Park; Hee Young Shin; Hyo Seop Ahn
Journal:  Korean J Hematol       Date:  2012-06-26

Review 7.  Regenerative stromal cell therapy in allogeneic hematopoietic stem cell transplantation: current impact and future directions.

Authors:  Jeffery J Auletta; Kenneth R Cooke; Luis A Solchaga; Robert J Deans; Wouter van't Hof
Journal:  Biol Blood Marrow Transplant       Date:  2009-12-16       Impact factor: 5.742

8.  Multistate modeling and simulation of patient trajectories after allogeneic hematopoietic stem cell transplantation to inform drug development.

Authors:  David A James; Jennifer Ng; Jiawei Wei; Marc Vandemeulebroecke
Journal:  Biom J       Date:  2018-09-17       Impact factor: 2.207

9.  Efficacy, Safety, and Practicality of Tacrolimus Monitoring after Bone Marrow Transplant: Assessment of a Change in Practice.

Authors:  Jacky Cheung; Jason Wentzell; Melanie Trinacty; Pierre Giguère; Priya Patel; Natasha Kekre; Tiffany Nguyen
Journal:  Can J Hosp Pharm       Date:  2020-02-01

Review 10.  Extracorporeal photopheresis versus alternative treatment for chronic graft-versus-host disease after haematopoietic stem cell transplantation in paediatric patients.

Authors:  Marcus Weitz; Brigitte Strahm; Joerg J Meerpohl; Maria Schmidt; Dirk Bassler
Journal:  Cochrane Database Syst Rev       Date:  2015-12-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.